
- Get in Touch with Us
Last Updated: Apr 26, 2025 | Study Period: 2024-2030
Atypical antipsychotics are a class of medications that includes ziprasidone. The mental illness schizophrenia, which involves erratic or strange thinking, a lack of interest in daily activities, and intense or inappropriate emotions, is treated with ziprasidone.
Manic depressive disorder, a condition that produces episodes of sadness, episodes of mania, and other abnormal moods, is also treated with it.
Manic depressive disorder is a condition that causes periods of depression, episodes of mania, and other aberrant moods.
Atypical antipsychotics are a group of medicines that includes ziprasidone. It functions by altering the way that a few organic brain chemicals behave.
It functions by assisting in the restoration of the equilibrium of some natural compounds in the brain.
Before starting to take ziprasidone and each time you get a refill, read the Patient Information Booklet if it is available from your chemist.
Ask your physician or chemist if you have any questions. Follow your doctor's instructions when taking this medication by mouth with food; typically twice daily.
Completely inhale the capsules. Avoid breaking or chewing the capsules. Your medical condition and treatment response will determine the dosage.
Your doctor might advise you to start this medicine at a low dose and gradually raise it in order to lower your risk of experiencing side effects.
Carefully adhere to your doctor's directions. To reap the greatest benefits from this drug, take it frequently. Take it at the same time every day to aid in memory.
Even if you feel OK, continue taking this medication. Without first consulting your doctor, do not discontinue using this drug.
The Global Ziprasidone Market accounted for $XX Billion in 2023 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2024 to 2030.
Following the US Food & Drug Administration's clearance of Dr. Reddy's ANDA for Ziprasidone Hydrochloride Capsules, Dr. Reddy's Laboratories launched Ziprasidone Hydrochloride Capsules, a bioequivalent generic form of Geodon.
Ziprasidone is available as a pill to swallow. It is often taken with food twice a day. Take ziprasidone every day at roughly the same time.
Ask your doctor or chemist to explain any instructions on your prescription label that you are unsure about following.
Follow the ziprasidone directions exactly. Never take it in larger or less amounts or more frequently than directed by your doctor. You might begin taking ziprasidone at a low dose and then gradually increase it, according to your doctor.
Although it won't treat your disease, ziprasidone may help you manage your symptoms. You may not experience ziprasidone's full benefits for a few weeks or longer. Even if you feel good, keep taking ziprasidone.
The medication ziprasidone is unstable and very lipophilic. An alternative form of this medication, ziprasidone nanoparticles, is used to treat illnesses.
The term "nanoparticle" is widely used to describe the existence of ziprasidone in the form of particles with an effective average crystal size of less than or equal to 100 nm.
Insufficient water solubility affects 40% of recently produced medications.Because they are poorly soluble in water, drugs have a low bioavailability.
Using cosolvents, surfactants, and complexing to manufacture pharmaceuticals as salts are just a few of the many ways to increase the solubility of poorly water-soluble medications. Particle size reduction medications may also increase their solubility, according to certain reports.
Medication using nanoscale-sized active ingredients is an example of an application of nanotechnology for chemists.
Smaller drug delivery systems allow medications to be deposited in previously inaccessible bodily areas, which is important for the diagnosis and treatment of particular diseases like cancer.
New breakthroughs in medical technology and diagnostic procedures, such as target treatment, are changing how medications are delivered.
There are some questions about these developments because the science that underpins nanotechnology is still in its infancy.
Ziprasidone nanosuspensions and nanoemulsions are composed of colloidal submicron dispersed ziprasidone particles.
An example of a formulation using solubilization technology is a nanosuspension of a crystalline basis free of ziprasidone.
Ziprasidone HCl has been formulated as a buffered nanoemulsion in an attempt to circumvent the drug's solubility problem and explore its potential for nose-to-brain delivery.
Because they are simple to work with, accepted by the US FDA, nontoxic, and precisely and selectively destroyed in the colon, nanoformulations represent a revolutionary approach to medication delivery.
Nanosuspensions and nanoemulsions have emerged as a feasible option for the efficient delivery of hydrophobic drugs due to their many benefits, including their extremely small particle size. Ziprasidone is available in numerous nanoformulations, including nanoemulsions and nanosuspensions.
Nanosuspension of a crystalline ziprasidone-free foundation is one formulation that uses solubilization technology. Ziprasidone hydrochloride is an example of an atypical antipsychotic medication.
It is a white or slightly pink powder that is essentially insoluble in water, but is marginally soluble at 300 °C, which is also the melting temperature of methylene chloride and methanol.
Due to its high permeability and low solubility, it is categorised as a BCS Class II drug.
The absolute bioavailability of the 20 mg dose in fed conditions was estimated to be around 60%. Peak plasma concentrations of ziprasidone hydrochloride are attained 6 to 8 hours after the oral dose thanks to the drug's efficient absorption from the digestive tract.
The cytochrome P450 isoenzyme CYP3A4 and aldehyde oxidase both substantially metabolise ziprasidone hydrochloride.
Sl no | Topic |
1 | Market Segmentation |
2 | Scope of the report |
3 | Abbreviations |
4 | Research Methodology |
5 | Executive Summary |
6 | Introduction |
7 | Insights from Industry stakeholders |
8 | Cost breakdown of Product by sub-components and average profit margin |
9 | Disruptive innovation in the Industry |
10 | Technology trends in the Industry |
11 | Consumer trends in the industry |
12 | Recent Production Milestones |
13 | Component Manufacturing in US, EU and China |
14 | COVID-19 impact on overall market |
15 | COVID-19 impact on Production of components |
16 | COVID-19 impact on Point of sale |
17 | Market Segmentation, Dynamics and Forecast by Geography, 2024-2030 |
18 | Market Segmentation, Dynamics and Forecast by Product Type, 2024-2030 |
19 | Market Segmentation, Dynamics and Forecast by Application, 2024-2030 |
20 | Market Segmentation, Dynamics and Forecast by End use, 2024-2030 |
21 | Product installation rate by OEM, 2023 |
22 | Incline/Decline in Average B-2-B selling price in past 5 years |
23 | Competition from substitute products |
24 | Gross margin and average profitability of suppliers |
25 | New product development in past 12 months |
26 | M&A in past 12 months |
27 | Growth strategy of leading players |
28 | Market share of vendors, 2023 |
29 | Company Profiles |
30 | Unmet needs and opportunity for new suppliers |
31 | Conclusion |
32 | Appendix |